BNOXN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetNear-zero debt materially reduces solvency and refinancing risk for a biotech with development-stage assets. A conservative capital structure preserves optionality to fund trials, partner deals, or absorb R&D setbacks without immediate debt pressure, supporting durability over months.
Recent Strong Cash GenerationMeaningful positive operating and free cash flow provides a multi-month runway, reduces immediate dilution needs and funds operations or strategic activities. While cash flow was volatile historically, current positive generation materially improves near-term funding flexibility and execution capacity.
Milestone / Licensing Revenue PotentialReceipt of milestone from Pfizer validates the value of legacy CTx licensing and creates a recurring optional revenue stream via future milestones/royalties. Structural licensing upside diversifies revenue beyond operations and could provide non-dilutive funding as programs progress.
Bears Say
Sharp TTM Income Statement DeteriorationA very large TTM net loss and a negative revenue period indicate major earnings instability. Persistent or recurring large operating losses erode capital, threaten runway absent new funding or partners, and weigh on sustainable margins and R&D financing over the medium term.
Erosion Of Shareholder EquityDeclining equity reduces the firm's capital buffer and long-term financial flexibility. As losses accumulate and book equity contracts, the company faces greater likelihood of needing dilutive capital raises or asset sales, complicating long-term program funding and strategic options.
Volatile Cash Flow / Sustainability RiskRecent positive cash flow follows periods of negative cash generation, highlighting volatility and dependence on episodic events (milestones, financing). Such variability raises the risk that current cash strength is temporary, potentially forcing future dilutive financing or delayed programs.
Neuphoria Therapeutics News
BNOXN FAQ
What was Neuphoria Therapeutics Inc.’s price range in the past 12 months?
Currently, no data Available
What is Neuphoria Therapeutics Inc.’s market cap?
Neuphoria Therapeutics Inc.’s market cap is $343.96M.
When is Neuphoria Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Neuphoria Therapeutics Inc.’s earnings last quarter?
Currently, no data Available
Is Neuphoria Therapeutics Inc. overvalued?
According to Wall Street analysts Neuphoria Therapeutics Inc.’s price is currently Undervalued.
Does Neuphoria Therapeutics Inc. pay dividends?
Neuphoria Therapeutics Inc. does not currently pay dividends.
What is Neuphoria Therapeutics Inc.’s EPS estimate?
Neuphoria Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuphoria Therapeutics Inc. have?
Neuphoria Therapeutics Inc. has 5,404,551 shares outstanding.
What happened to Neuphoria Therapeutics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neuphoria Therapeutics Inc.?
Currently, no hedge funds are holding shares in MX:BNOXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neuphoria Therapeutics Inc.
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.